Congress moves to cap drug prices at international levels, bypassing pharma lobbying

What it does

This bill directs the Secretary of Health and Human Services to create rules that cap U.S. drug prices at levels comparable to those paid in other wealthy countries (a 'most-favored-nation' pricing model), allows individuals to import cheaper prescription drugs from developed nations, and instructs federal enforcement agencies to pursue antitrust cases against pharmaceutical companies for anticompetitive practices. The goal is to reduce what Americans pay for prescription drugs by benchmarking them to international prices.

Why we flagged it

The bill's core mechanism is price regulation and enforcement against pharmaceutical manufacturers to reduce consumer costs. It is fundamentally a consumer-protection and price-control measure, not a subsidy, carve-out, or commemorative act.

What the text implies

• Most-favored-nation pricing may incentivize pharmaceutical companies to raise prices in other developed countries to offset U.S. losses, shifting cost burden internationally.
• Individual drug importation certification could create supply-chain complexity and potential counterfeit-drug risks if enforcement mechanisms are weak.
• Direct-to-consumer purchasing programs may bypass pharmacy benefit managers and insurance intermediaries, disrupting existing healthcare financing models.
• The study of 'unreasonable or discriminatory behavior' and 'subsidization of global R&D' may lay groundwork for future trade disputes or tariffs on pharmaceutical imports.

Who it affects

Ordinary Americans would likely pay less for prescription drugs under this bill, as it directly targets price reduction through international benchmarking and importation. The primary beneficiaries are patients and consumers facing high drug costs; the primary costs fall on pharmaceutical manufacturers' profit margins, not on the public.

Who stands to gain

• patients and consumers (lower out-of-pocket drug costs)
• pharmacy benefit managers (potential new direct-to-consumer channel)
• generic drug manufacturers (increased competitive pressure on branded drugs)

Named in the bill

Secretary of Health and Human Services (HHS), Centers for Medicare & Medicaid Services (CMS), Attorney General, Federal Trade Commission (FTC), Secretary of Commerce (SecDOC), U.S. Trade Representative, Bristol Myers Squibb (BMY), Gilead Sciences (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ), Sherman Act — and 2 more

Where it stands

7 cosponsors: 5 Republicans, 2 Democrats.

• May 19, 2025 — Introduced · Congress.gov: “Introduced in House”
• May 19, 2025 — Referred to House Committee on the Judiciary and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $3,010,000 in lobbying spend. A filing names 77 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Ro Khanna, the sponsor, reported $0 in PAC receipts in the 2026 cycle.

• America's Health Insurance Plans Inc (ahip) — $3,010,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.